Nonetheless, a 2020 study did indicate that patients with secondary AML present with a higher fraction of CD34+CD38– cells compared to patients with de novo AML,28 however further studies will ultimately be needed to determine whether these markers accurately identify true LSCs in patients with secondary AML who have progressed, or can identify pre-LSCs. This evidence concerns the gene CD38 and acute myeloid leukemia.